Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new ALS drug is showing early promise. QurAlis's QRL-201, an antisense oligonucleotide targeting a splicing defect in the STMN2 gene, demonstrated target engagement, reduced neurofilament levels, and a trend toward slower functional decline in interim phase 1 trial data. The company is now gearing up for a pivotal phase 3 trial in 2027.
A new investigational therapy for ALS is generating buzz after encouraging interim results. QurAlis presented data from its phase 1 ANQUR trial at the 2026 Northeast ALS Consortium Annual Meeting, showing that QRL-201 — an antisense oligonucleotide designed to correct a splicing defect in the STMN2 gene — successfully engaged its target, reduced neurofilament biomarker levels, and showed a trend toward slowing functional decline in people with sporadic and C9orf72-related ALS.
STMN2 is a protein critical for neuronal repair and axonal stability, and its mis-splicing is a hallmark finding in ALS tissue. QRL-201 is delivered intrathecally and aims to restore normal STMN2 function. In a post hoc analysis excluding patients with the highest baseline neurofilament levels (a marker of faster disease progression), sporadic ALS patients showed a statistically significant and clinically meaningful slowing of functional decline at 26 weeks. The drug was generally well tolerated, with mostly mild to moderate side effects.
Key Takeaways:
Why it matters: ALS remains a devastating disease with very limited treatment options. QRL-201's early data — combining biological target engagement with a functional signal — offers a meaningful step forward for a precision medicine approach in a disease that has historically resisted treatment.
